Genfit S.A. Asset Resilience Ratio
Genfit S.A. asset resilience ratio. Genfit S.A. (GNFT) has an Asset Resilience Ratio of 0.78% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GNFT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genfit S.A. (2004–2024)
Asset resilience ratio of Genfit S.A. from 2004 to 2024. This chart shows how Genfit S.A.'s Asset Resilience Ratio has changed over time. Read Genfit S.A. (GNFT) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genfit S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Genfit S.A..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.18 Million | 0.78% |
| Total Liquid Assets | $1.18 Million | 0.78% |
Asset Resilience Insights
- Limited Liquidity: Genfit S.A. maintains only 0.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genfit S.A. Industry Peers by Asset Resilience Ratio
Compare Genfit S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Genfit S.A. Asset Resilience Ratio by Year (2004–2024)
Genfit S.A. asset resilience ratio by year from 2004 to 2024. The table below shows the annual Asset Resilience Ratio data for Genfit S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.78% | $1.18 Million | $151.42 Million | +0.78pp |
| 2023-12-31 | 0.00% | $1.00K | $173.87 Million | -2.11pp |
| 2022-12-31 | 2.11% | $4.55 Million | $215.54 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $281.72 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $309.85 Million | -- |
| 2018-12-31 | 54.17% | $124.32 Million | $229.48 Million | +6.77pp |
| 2017-12-31 | 47.40% | $138.97 Million | $293.18 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $166.21 Million | -- |
| 2015-12-31 | 0.03% | $22.00K | $69.26 Million | -4.61pp |
| 2014-12-31 | 4.64% | $4.01 Million | $86.37 Million | +4.64pp |
| 2013-12-31 | 0.00% | $400.00 | $29.15 Million | -0.07pp |
| 2012-12-31 | 0.08% | $18.00K | $23.58 Million | +0.03pp |
| 2011-12-31 | 0.05% | $13.80K | $29.08 Million | -1.96pp |
| 2008-12-31 | 2.00% | $921.40K | $45.99 Million | -1.85pp |
| 2007-12-31 | 3.85% | $1.55 Million | $40.21 Million | +0.60pp |
| 2006-12-31 | 3.25% | $1.50 Million | $46.24 Million | -2.21pp |
| 2005-12-31 | 5.46% | $1.68 Million | $30.83 Million | -33.51pp |
| 2004-12-31 | 38.96% | $11.93 Million | $30.61 Million | -- |
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more